DCTY0801
/ Beijing DCTY Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
October 09, 2025
China‑based Northeast Pharmaceutical Group…has announced that its chimeric antigen receptor T‑cell therapy, DCTY0801 Injection, has received clearance from the National Medical Products Administration (NMPA) to initiate clinical trials for patients with recurrent or progressive high‑grade brain gliomas expressing the EGFRvIII mutant antigen
(flcube.com)
New trial • Glioma
August 25, 2023
A Study to Evaluate the Safety, Tolerance and Initial Efficacy of EGFRvIII CAR-T on Glioblastoma
(clinicaltrials.gov)
- P1 | N=22 | Not yet recruiting | Sponsor: Beijing Tsinghua Chang Gung Hospital | Trial completion date: Jul 2025 ➔ Nov 2025 | Initiation date: Jul 2023 ➔ Nov 2023 | Trial primary completion date: Jul 2025 ➔ Nov 2025
IO biomarker • Trial completion date • Trial initiation date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor
June 05, 2023
A Study to Evaluate the Safety, Tolerance and Initial Efficacy of EGFRvIII CAR-T on Glioblastoma
(clinicaltrials.gov)
- P1 | N=22 | Not yet recruiting | Sponsor: Beijing Tsinghua Chang Gung Hospital | Trial completion date: Apr 2025 ➔ Jul 2025 | Initiation date: Apr 2023 ➔ Jul 2023 | Trial primary completion date: Apr 2025 ➔ Jul 2025
IO biomarker • Trial completion date • Trial initiation date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor
1 to 3
Of
3
Go to page
1